Abdi Ibrahim Pharmaceuticals (“Abdi Ibrahim”) and APR Applied Pharma Research SA (“APR”), together with its joint venture partner Labtec GmbH (“Labtec”), today announced that they have entered into an exclusive licensing agreement under which Abdi Ibrahim has the exclusive rights to market Ondansetron Rapidfilm® in Turkey.